Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MI

Area of Science:

• Cardiology
• Vascular Biology
• Pharmacology

Background:

• The AEGIS-II trial investigated CSL112 (intravenous human apolipoprotein A-I) for reducing recurrent myocardial infarction (MI) in high-risk patients.
• The hypothesis centered on CSL112's potential to decrease plaque disruption and subsequent cardiovascular events.

Purpose of the Study:

• To explore the impact of CSL112 therapy on the incidence of cardiovascular death and recurrent MI.
• This analysis aimed to evaluate CSL112's efficacy in a high-risk MI population.

Main Methods:

• AEGIS-II was an international, randomized, double-blind, placebo-controlled trial involving 18,219 high-risk acute MI patients.
• Participants received four weekly infusions of either CSL112 (6 g apoA-I) or a placebo.

Main Results:

• The composite of cardiovascular death and type 1 MI showed a trend towards reduction with CSL112 (e.g., HR 0.86, P=0.048 at 180 days).
• Rates of cardiovascular death or any MI were numerically lower in the CSL112 group throughout follow-up.
• CSL112 demonstrated a notable effect on type 1 MI and MI due to stent thrombosis (type 4b).

Conclusions:

• CSL112 did not meet statistical significance for primary endpoints but showed numerically lower rates of CV death and MI.
• Findings suggest apolipoprotein A-I may reduce plaque disruption via enhanced cholesterol efflux.
• Further prospective research is warranted to validate these observations and CSL112's role.